Building Blocks Catalog

284 Thousand compounds in stock

Original and unique

Make-on-demand
Building Blocks

210 Million novel building blocks

Reliable supply

Custom Synthesis

Over 650 highly skillful chemists

Unique synthesis technologies

Library Synthesis

36B Billion REAL compounds and

Custom Library Synthesis

FTE Chemistry Support

On site access to all Enamine stock BB’s

Highly flexible arrangements

2 000 new building blocks are synthesized monthly. Here is an important update to our MedChem Highlights from May 2023

Recent News

  • 22 May 2023   Press Releases

    Enamine Launches a New Chemistry Site in Germany

    Welcome to the latest update from Enamine - we're delighted to share our growth story with you. In our continued pursuit of scientific excellence and global expansion, we've launched a new subsidiary, Enamine Germany GmbH, based in Frankfurt's Höchst Industrial Park. This significant development strengthens our commitment to provide more localized and efficient services in organic synthesis and medicinal chemistry.

  • 27 April 2023   Press Releases

    Nostrum Biodiscovery and ENAMINE Join Forces to Develop a ...

    Barcelona, Spain, and Kyiv, Ukraine, April 27, 2023. Nostrum Biodiscovery, a leading provider of computational drug discovery services, and ENAMINE, a global supplier of chemical building blocks and screening compounds, announced today a groundbreaking collaboration for the co-development of a revolutionary search engine tailored for the REAL Space billion database. This partnership aims to deliver unparalleled performance in searching vast chemical spaces while utilizing low computational resources, thus increasing the efficiency and accessibility of drug discovery efforts.

    The collaboration will also focus on enhancing High Throughput Virtual Screening (HTVS) services to streamline the drug discovery process. Nostrum Biodiscovery's state-of-the-art AI-enabled screening platform will take center stage in this effort, boasting the capability to evaluate the entire billion compound collection in just hours. This innovative technology promises to identify potential drug candidates within weeks, significantly accelerating the discovery pipeline.

    ENAMINE’s expertise in the rapid and reliable provision of compounds will further strengthen the collaboration, ensuring that researchers have timely access to the vast array of molecules in the REAL Space database. This partnership will facilitate the seamless integration of Nostrum Biodiscovery's computational prowess with ENAMINE’s extensive compound collection, directly impacting companies interested in using services offered by both partners and ultimately benefiting the global scientific community and accelerating the path to new drug discoveries.

    [Victor Guallar, CSO Nostrum Biodiscovery] “We see it every day in our projects, using the REAL Space database with our AI/MM hybrid HTVS platform is a game changer in finding molecules. Our joint venture with ENAMINE demonstrates our commitment to integrating cutting-edge technology and high-quality compound collections to provide the pharmaceutical industry with unparalleled access to resources that expedite drug discovery. We believe that this partnership will serve as a catalyst for innovation, inspiring ventures to explore uncharted territories in the quest for novel therapeutics.”

    [Andrey Tarnovskiy, Sales Director, Europe at Enamine] “This year the size of Enamine’s REAL Space has reached tremendous 36 Billion compounds. We are excited to cooperate with Nostrum Biodiscovery to complement the available suite of search tools for REAL Space exploration with brand-new AI-based solution for high-throughput virtual screening and hope that our synergy will allow to facilitate and strengthen the drug discovery efforts of our customers.”

    Read Press Release

  • 19 April 2023   Press Releases

    Enamine and Endogena Therapeutics – a Successful, Multi-Year Drug ...

    Kyiv, Ukraine, April 19, 2023 - Enamine Ltd., a provider of drug discovery services empowered with the world’s largest collections of building blocks, fragments, and screening compounds, gave an update of its long-standing research collaboration with Endogena Therapeutics AG, a clinicalstage biotech company focused on the development of endogenous regenerative medicines.

    Enamine provides Endogena with its integrated capability in medicinal chemistry to support Endogena’s small molecule drug discovery programs in the fields of hit finding, hit-to-lead and lead optimization.

    The companies have been collaborating under a Full Time Equivalent (FTE) model since 2019. The two discovery partners have been continuing their research collaboration to date, their research relationship not being impacted by the war in Ukraine. This collaboration extension, along with many others and new ones established by Enamine since February 24, 2022, already under the conflict, is a systematic positive trend experienced by the company, that demonstrates the support of its customers and the trust they have in receiving high-quality service backed up by the unparalleled number of diverse building blocks available at Enamine.

    Sven Weiler, Vice President of Medicinal Chemistry at Endogena, commented: “The interaction with colleagues from Enamine has been a smooth one from the start. In addition to the FTE model, it is great to have access to their huge compound collection and be able to flexibly use Enamine’s capacity to its full potential. We value the output and responsiveness of the Enamine team, helping us to achieve our demanding milestones. It is stunning to see how well Enamine has been able to keep pace after February 2022.”

    Michael Bossert, Head of Strategic Alliances at Enamine, added: “After 13 months of the war in the country, we are especially pleased to announce our collaboration with Endogena, a longlasting partner we have been serving during those several years with extensive medicinal chemistry and SAR efforts”.

    Read Press Release

Upcoming events

  • Sep 3-7

    Delegation

  • Jul 5-7

    Delegation

  • Jun 18-22

    Sponsoring

    International Summer School on Organic Synthesis "A. Corbella" - ISOS 2023

Bioactive Library

Collection of referred small molecules with carefully collected activity data

2 320 compounds

To address continuously growing interested to Drug Repurposing we designed and carefully collected a Bioactive Reference Collection of over 2 300 compounds with extensive target classes’ coverage and the broadest possible therapeutic areas applications – from CNS agents and anti-infectives to anticancer drugs and steroids.

Request

Represented collection of carefully selected compounds includes 1 040 FDA approved drugs, as well as “tool compounds” with validated biological activity, active metabolites/prodrugs, and drug candidates that are currently undergoing clinical trials.

Ready-to-use, fully referred, alternative for compound screening.

Any compound from BRC collection can be ordered individually as focused sets: target-based or by therapeutic area.

Proven and reliable

  • Stringent quality control using most advanced methods.
  • Synthetic chemistry capacity with professionals in organic chemistry experienced in diverse synthetic methods and techniques.
  • Drugs synthesis and their functional modifications for target identification and other purposes.

Distribution of compounds by therapeutic area

Related products & services

Target identification toolbox

Additionally we provide broad functionalization of Drugs and relative actives with covalent warheads, biotin or/and dye-linking, PED-derivatization and other modifications. Versatile chemistry and the largest stock of valuable reagents enables Enamine to produce new functionalization of well-known drugs.

We combined most diverse approaches and possible structural modifications to achieve most complete representation of our Target identification tools.

We offer over 60 ready-to-deliver pre-plated compound libraries in a variety of custom formats. Our well-equipped liquid handling department will make a library copy in any convenient for you project format.

Diversity Libraries

Product name
Size
Description
Download file

Format/Size

460 160 compounds

Description

The largest diversity library with high MedChem tractability

Download file

&nsbp;

Size

50 240 compounds

Descriptions

Top-quality diverse library of recently synthesized compounds

Download file

&nsbp;

Size

10 240 compounds

Descriptions

High-quality diverse library of latest compounds

Download file

&nsbp;

Size

11 760 compounds

Descriptions

Diverse covalent library with most demanded warhead types

Download file

&nsbp;

Size

5 760 compounds

Descriptions

Special diversity library created for Phenotypic Screens

Download file

&nsbp;

PAINS Library

PAINS-320

Size

320 compounds

Descriptions

Special diverse selection of frequent hitters

Download file

&nsbp;

Covalent Libraries

Product name
Size
Descriptions
Download file

Size

11 760 compounds

Descriptions

Diverse covalent library with most demanded warhead types

Download file

&nsbp;

Size

12 160 compounds

Descriptions

Designed for discovery of mild electrophilic inhibitors of the largest enzyme class

Download file

&nsbp;

Size

2 640 compounds

Descriptions

Designed for the discovery of new SARS-CoV-2 and pan-Coronavirus antivirals

Download file

&nsbp;

Size

7 360 fragments

Descriptions

Diverse covalent warheads with balanced reactivity

Download file

&nsbp;

Size

3 200 fragments

Descriptions

Library of Cys-specific covalent electrophilic binders

Download file

&nsbp;

Size

1 600 fragments

Descriptions

Special selection of Serine focused irreversible binders

Download file

&nsbp;

Size

1 600 fragments

Descriptions

A unique set of 1 600 Lys specific binders

Download file

&nsbp;

Size

960 fragments

Descriptions

Characterized by a new HTS thiol-reactivity assay

Download file

&nsbp;

Acrylamide Library

sACR-4080

Size

4 080 compounds

Descriptions

Diverse screening Acrylamides pre-plated at 10 mM concentration

Download file

&nsbp;

Size

2 240 compounds

Descriptions

Representative selection of fragment Acrylamides pre-plated at 100 mM stock concentration

Download file

&nsbp;

Chloroacetamides

sCLA-1200

Size

1 200 compounds

Descriptions

Library of diverse HTS-size chloroacetamides pre-plated at 10 mM concentration

Download file

&nsbp;

Size

1 360 compounds

Descriptions

Diverse strict Ro3 compliant chloroacetamides plated at 100 mM stock concentartion

Download file

&nsbp;

Size

1 120 compounds

Descriptions

Representative selection of N-, O-linked and Aryl sulfonyl fluorides within fragment space

Download file

&nsbp;

Targeted Libraries

Product name
Size
Descriptions
Download file

Size

10 240 compounds

Descriptions

Library of compounds intended for use in agro/crop science

Download file

&nsbp;

Size

14 400 compounds

Descriptions

Designed for discovery of novel allosteric ligands

Download file

&nsbp;

Size

4 800 compounds

Descriptions

Carefully selected molecules via docking and visual evaluation

Download file

&nsbp;

Size

3 200 compounds

Descriptions

Designed for discovery of new Nucleoside-like antivirals

Download file

&nsbp;

Size

10 560 compounds

Descriptions

Designed for discovery of new Voltage-gated calcium channel blockers

Download file

&nsbp;

CNS Library

CNS-47

Size

47 360 compounds

Descriptions

Library of novel small molecules with high CNS MPO scores

Download file

&nsbp;

Size

16 800 compounds

Descriptions

Designed for the discovery of new SARS-CoV-2 and pan-Coronavirus antivirals

Download file

&nsbp;

Size

2 470 compounds

Descriptions

Specially synthesized set of compounds able to mimic glycosides and their interaction with proteins

Download file

&nsbp;

GPCR Library

GPR-54

Size

54 080 compounds

Descriptions

Designed for discovery of new GPCR ligands

Download file

&nsbp;

Size

24 000 compounds

Descriptions

Designed for discovery of novel kinase ATP pocket binders

Download file

&nsbp;

Size

1 003 compounds

Descriptions

IDO focused library designed by a combination of structure- and ligand-based methods

Download file

&nsbp;

Size

36 800 compounds

Descriptions

Designed for discovery of new Ion Channels ligands

Download file

&nsbp;

Kinase Library

KNS-64960

Size

64 960 compounds

Descriptions

Designed for discovery of novel protein kinase inhibitors

Download file

&nsbp;

Size

5 440 compounds

Descriptions

A sub-library of Enamine’s GPCR Library designed for discovery of novel lipid GPCR ligands

Download file

&nsbp;

Size

2 468 compounds

Descriptions

A set of compounds focused on targeting molecular chaperones

Download file

&nsbp;

Size

320 compounds

Descriptions

Small library of specially synthesized compounds

Download file

&nsbp;

Size

1 920 compounds

Descriptions

Sublibrary of PPI-40

Download file

&nsbp;

Size

8 960 compounds

Descriptions

Selected molecules able to mimic common protein motifs

Download file

&nsbp;

Size

40 640 compounds

Descriptions

Designed for discovery of novel PPI inhibitors

Download file

&nsbp;

RNA Library

RNA-15520

Size

15 520 compounds

Descriptions

Library of compounds capable of binding to RNA

Download file

&nsbp;

Size

12 160 compounds

Descriptions

Designed for discovery of mild electrophilic inhibitors of the largest enzyme class

Download file

&nsbp;

Size

5 440 compounds

Descriptions

Designed for discovery of new Nav1.7 channel blockers

Download file

&nsbp;

Bioactive Libraries

Product name
Size
Descriptions
Download file

CLOUD

CLOUD-293

Size

293 compounds

Description

Represents the diversity of structures and molecular targets of all FDA-approved chemical entities (Nat Chem Biol 13 (2017), 771–778)

Download file

&nsbp;

Size

1 040 compounds

Description

Most relevant selection of drugs in one formulation/no duplicates. Contains WHO List of Essential Medicines including Lapatinib and latest approved drugs such as Tivozanib, etc.

Download file

&nsbp;

Size

2 320 compounds

Descriptions

Actives with extensive target classes’ coverage and the broadest possible therapeutic areas applications – from CNS agents and anti-infectives to anticancer drugs, steroids and molecular glues.

Download file

&nsbp;

Size

5 760 compounds

Description

Library of cell penetrated compounds and their closest analogs. Covers diverse therapeutic areas from antitumor, neurology and antibacterial to aging diseases.

Download file

&nsbp;

PAINS Library

PAINS-320

Size

320 compounds

Description

Frequent hitters with most diverse scaffold selection – from small hydroquinone and other covalent modifiers to polyfluorinated highly lipophilic molecules and dyes.

Download file

&nsbp;

Fragment Libraries

Product name
Size
Description
Download file

Size

320 compounds

Description

Elaborated tool for initial screen

Download file

&nsbp;

Size

1 920 compounds

Description

Fragments of high MedChem tractability

Download file

&nsbp;

Size

860 compounds

Description

Designed for easy and rapid follow-up synthesis

Download file

&nsbp;

MiniFrag Library

MiniFrag-80

Size

80 compounds

Description

Guiding optimisation of fragment-derived lead compounds

Download file

&nsbp;

Size

7 360 fragments

Description

Diverse covalent warheads with balanced reactivity

Download file

&nsbp;

Size

1 000 compounds

Description

Specially designed for 19F NMR ligand-based screening

Download file

&nsbp;

Size

640 fragments

Description

Designed for easy and efficient exploration of novel protein targets

Download file

&nsbp;

Size

4 160 compounds

Description

Source of biologically validated starting points

Download file

&nsbp;

Size

1 200 compounds

Description

Unique 3D diversity among shaped molecules

Download file

&nsbp;

Size

3 600 compounds

Description

Fragments able to mimic protein structural motifs and hot-spot residues

Download file

&nsbp;

Size

1 500 compounds

Description

Fragments for easy-to-analyse protein-ligand interaction

Download file

&nsbp;

Size

4 000 compounds

Description

Designed for specific protein targets and sensible onset

Download file

&nsbp;

Size

960 fragments

Description

Characterized by a new HTS thiol-reactivity assay

Download file

&nsbp;

PAINS Library

Special diverse selection of frequent hitters

320 compounds

Pan-Assay Interference Compounds (PAINS) are the most recognized filters among medicinal chemists. Since first publication in 2010 by John Bell these filters have become industry standard in Drug Discovery. While carefully removing all PAINS-related compounds from Enamine libraries we realized that these compounds can be very useful in HTS assay set-up & validation.

Request

Special diversity set of PAINS available for prompt delivery in various plated formats including the most popular listed below:

Typical Formats

Catalog No.
Compounds
Amount
Format
Price

Catalog No.

PAINS-320-10-Y-10

Compounds

320
1 plate

Amount

10 μL of 10 mM DMSO solutions

Plates and formats

384-well acoustic plates, Labcyte #PP-0200,
last two columns empty;

Price

This email address is being protected from spambots. You need JavaScript enabled to view it.

Catalog No.

PAINS-320-50-Y-10

Compounds

320
1 plate

Amount

50 μL of 10 mM DMSO solutions

Plates and formats

384-well plates, Greiner #784201,
1, 2 and 23, 24 columns empty;
320 compounds per plate

Price

This email address is being protected from spambots. You need JavaScript enabled to view it.

Catalog No.

PAINS-320-100-X-10

Compounds

320
4 plates

Amount

100 μL of 10 mM DMSO solutions

Plates and formats

96-well plates, Greiner #65021,
1 and 12 columns empty;
80 compounds per plate

Price

This email address is being protected from spambots. You need JavaScript enabled to view it.

Catalog No.

PAINS-320

Compounds

320

Amount

Custom

Plates and formats

Any custom format

Price

This email address is being protected from spambots. You need JavaScript enabled to view it.

Library design

The design is based on substructural motifs of known PAINS compounds. We used originally reported PAINS filters to identify a set of over 80k in-stock compounds. This set was clustered using fingerprint-based approach and Tanimoto similarity distance calculations. The most populated clusters with at least 5 compounds were extracted and one representative example was selected from each cluster resulting in a library of 320 compounds. The library of most diverse 320 PAINS is available in plate format for your convenience. Examples are given below.

Key features

  • Represents the most common false positives
  • Substructure & scaffold diversity
  • All compounds suitable for storage as DMSO solutions

Example of structures and their specific PAINS filters

Diversity Libraries

Product name
Size
Description
Download file

CLOUD

CLOUD-293

Size

293
compounds

Description

Represents the diversity of structures and molecular targets of all FDA-approved chemical entities (Nat Chem Biol 13 (2017), 771–778)

Download file

Size

1 040
compounds

Description

Most relevant selection of drugs in one formulation/no duplicates. Contains WHO List of Essential Medicines including Lapatinib and latest approved drugs such as Tivozanib, etc.

Download file

Size

2 320
compounds

Description

Actives with extensive target classes’ coverage and the broadest possible therapeutic areas applications – from CNS agents and anti-infectives to anticancer drugs, steroids and molecular glues.

Download file

Size

5 760
compounds

Description

Library of cell penetrated compounds and their closest analogs. Covers diverse therapeutic areas from antitumor, neurology and antibacterial to aging diseases.

Download file

PAINS Library

PAINS-320

Size

320
compounds

Description

Frequent hitters with most diverse scaffold selection – from small hydroquinone and other covalent modifiers to polyfluorinated highly lipophilic molecules and dyes.

Download file

Get more details

Focused Sets

Target / Therapeutic Area
Size
Description
Download file

Target / Therapeutic Area

Angiogenesis

Size

184
compounds

Description

Angiogenesis related ligands targeting FLT3, DYRK1A, Collagenase 3, GAK, Bcr-Abl, BTK, EGFR etc.

Download file

Target / Therapeutic Area

Apoptosis

Size

38
compounds

Description

Apoptosis related ligands targeting Mdm2 Mcl-1 IAP Caspase Modulator I, Caspase 3 and Caspase 6, Bcl-2, p53, TNF-alpha.

Download file

Target / Therapeutic Area

Cancer Immunology

Size

390
compounds

Description

Molecules used for immune-oncology research targeting P2X3 receptor MAG lipase, PI3 kinase and P2Y12.

Download file

Target / Therapeutic Area

Cell Cycle

Size

94
compounds

Description

Сell cycle related compounds, e.g. LDC000067 CDK12-In-2 and Palbociclib selective and pan-CDK inhibitors, ROCK, mTOR and Aurora kinase inhibitors.

Download file

Target / Therapeutic Area

Epigenetics

Size

158
compounds

Description

Epigenetics related compounds targeting HDACs, HMT, JMJD, DNMT, Bromodomains, i KDM5 inhibitors and Sirtuin.

Download file

Target / Therapeutic Area

GPCRs

Size

738
compounds

Description

Bioactive GPCR-targeted molecules, including GPCR inhibitors, agonists, and allosteric modulators. Library represents actives against 195 unique GPCR targets.

Download file

Target / Therapeutic Area

Growth Factors Cytokines

Size

130
compounds

Description

Growth factors and cytokines ligands, including Ceritinib ALK inhibitor, Lucitanib VEGFR and FGFR inhibitor, MSX-127 CXCR4 antagonist, Eltrombopag Thrombopoietin receptor agonist etc.

Download file

Target / Therapeutic Area

Ion Channels

Size

300
compounds

Description

Ligands with annotated activity against 6 ion channel families and 105 unique targets. The library covers major applications typical for ion channel: cardiovascular regulation, neuroscience, immune response regulation.

Download file

Target / Therapeutic Area

JAK-STAT

Size

104
compounds

Description

JAK-STAT signalling targeted molecules, including Pazopanib multi-TK inhibitor, LY294002 TPK inhibitor, PF06700841 JAK1 inhibitor, SH-4-54 STAT3 inhibitor and other related actives.

Download file

Target / Therapeutic Area

Kinases

Size

366
compounds

Description

Kinase binders, including approved drugs Imatinib, covalent Ibrutinib, Dasatinib and highly active inhibitors of most important kinases such as RAF, MAPK, BTK and many other.

Download file

Target / Therapeutic Area

Membrane Receptors

Size

745
compounds

Description

Membrane receptors ligands, including Risperidone (5-HT2 receptor blocker, D2 receptor antagonist), VU0071063 (ATP-dependent potassium channel activator), CU-T12-9 (TLR1/2 antagonist), LY354740 (mGlu2/3 receptor agonist).

Download file

Target / Therapeutic Area

Nuclear Hormone Receptors

Size

160
compounds

Description

Nuclear receptor ligands with referenced activity against 368 unique molecular targets, including agonists Dienogest, antagonists Darolutamide, inverse antagonists GSK805.

Download file

Target / Therapeutic Area

Protease Inhibitors

Size

175
compounds

Description

High activity ligands against 104 human and pathogenic proteases, including Saxagliptin, anti-diabetic type 2 drug, Mpro SARS-CoV-2 inhibitors, Atazanavir HIV-1 protease inhibitor etc.

Download file

Target / Therapeutic Area

Signal Transduction

Size

254
compounds

Description

Signal transduction related ligands, including Selatinib EGFR/HER-2 inhibitor, XAV-939 Tankyrase1/2 inhibitor, STING agonist-1 G10, Fedratinib broad spectrum kinase inhibitor etc.

Download file

Target / Therapeutic Area

Transporters

Size

169
compounds

Description

Molecules with annotated activity against 12 transporter families and 82 unique targets, including Paroxetine (serotonin reuptake inhibitor), ML-352 (choline transporter 1 inhibitor, AR- C155858 (MCT1 and MCT2 inhibitor, GABA receptor ligands etc.

Download file

Fully Functionalized Probe Library

Designed for easy and efficient exploration of novel protein targets

640 compounds

Fully functionalized probes are designed to speed up and simplify early stages of drug development. Introduction of the diazirine photocrosslinking moiety along with the presence of functional acetylene group allow screening of compounds directly in cells. Originally described in the Cell paper by Ben Cravatt this approach has been adopted by other research groups to a number of successful project, including recently reported by GSK researchers ‘direct-to-biology’ high-throughput chemistry screening platform.

Request

Enamine currently has almost 6 000 fully functionalized compounds in stock and more than 1 milliom molecules in REAL Database.

The most diverse compounds have been selected and sorted out into a small library, which has been pre-plated for most convenient and fast delivery to our clients.

Typical Formats

Catalog No.
Compounds
Amount
Format
Price

Catalog No.

FFP-640-10-Y-20

Compounds

640
2 plates

Amount

10 µL of 20 mM DMSO solutions

Plates and formats

384-well echo plates Labcyte Cat. No PP-0200,
first two and last two columns empty,
320 compounds per plate

Price

This email address is being protected from spambots. You need JavaScript enabled to view it.

Catalog No.

FFP-640-50-Y-10

Compounds

640
2 plates

Amount

50 µL of 10 mM DMSO stock solutions

Plates and formats

384-well plates Greiner Cat. No. 781270,
1,2 & 23,24 columns empty,
320 compounds per plate

Price

This email address is being protected from spambots. You need JavaScript enabled to view it.

Catalog No.

FFP-640-100-Y-10

Compounds

640
8 plates

Amount

100 µL of 10 mM DMSO stock solutions

Plates and formats

96-well plates, Greiner Cat. No 650201, round (U) bottom,
1 & 12 columns empty,
80 compounds per plate

Price

This email address is being protected from spambots. You need JavaScript enabled to view it.

Catalog No.

FFP-640

Compounds

640

Amount

Custom

Plates and formats

Any custom format

Price

This email address is being protected from spambots. You need JavaScript enabled to view it.

Key features

  • Discovery of novel tractable protein targets
  • Identification of the binding site of the POI
  • Screening directly in cells
  • Easy hit confirmation via LC-MS
  • Next generation libraries can be rapidly synthesized through parallel chemistry

We refined our parallel chemistry protocols to synthesize photoaffinity labelled compounds, allowing our clients to rapidly access follow-up libraries based on the initial screening results.

Fully functionalized library has been designed based on the fragments with experimentally confirmed solubility in aqueous PBS at 1 mM concentration. In addition, we try to cover as much structural diversity as possible to have a different chemotypes and pharmacophores within a limited number of compounds.

Examples of the molecules in the library

Molecular Properties

FOLLOW US